最新影响因子将突破2.5分，这本肿瘤学SCI期刊诚邀投稿

Core Insights - The article discusses the latest research published in the journal "Clinical Medicine Insights: Oncology," focusing on cancer research and treatment, including various aspects such as molecular biology, genetics, and clinical interventions [4]. Group 1: Journal Overview - "Clinical Medicine Insights: Oncology" is an international, peer-reviewed open access journal that publishes articles on all aspects of cancer research and treatment [2]. - The journal currently has an impact factor (IF) of 1.9, with a predicted increase to 2.5 in the upcoming update [3]. Group 2: Recent Research Highlights - A recent clinical study titled "Effectiveness and Safety of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma" included 48 patients with unresectable hepatocellular carcinoma (uHCC), showing an objective response rate (ORR) of 39.6% and a disease control rate (DCR) of 70.8% based on RECIST 1.1 criteria [6][8]. - The study found that 75% of patients experienced adverse events, with the most common being thrombocytopenia (27.1%), lymphocytopenia (25%), and liver function abnormalities (14.6%) [8][9]. Group 3: AI in Colorectal Cancer Treatment - A highly cited paper discusses the applications of artificial intelligence (AI) in colorectal cancer treatment, highlighting its potential to predict treatment outcomes and guide personalized treatment strategies [11][14]. - The review included 49 relevant papers, indicating that AI shows promising results in treatment strategy selection and prognosis assessment for colorectal cancer patients [14]. Group 4: Multi-Omics Approaches in Cancer Research - Another notable paper emphasizes the integration of multi-omics methodologies, which combine genomics, transcriptomics, proteomics, and metabolomics, to enhance understanding of cancer biology and improve personalized treatment [16][18]. - The advancements in proteomics and mass spectrometry are expected to improve the accuracy of predicting treatment responses, thereby benefiting drug development and patient outcomes [18].